We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

2 hedge funds and large institutions have $0 invested in Sanofi Contingent Value Rights in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 98 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% less funds holding

Funds holding: 103 → 2 (-101)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $140M → $0 (-$140M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 98

Holders
2
Holders Change
-101
Holders Change %
-98.06%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
98
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonehill Capital Management
New York
-$46.8M
2
MCM
Mason Capital Management
New York
-$12.6M
3
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$11.4M
4
BCM
Brigade Capital Management
New York
-$11M
5
FCM
Farallon Capital Management
California
-$7.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonehill Capital Management
New York
– -$46.8M -54,410,668 Closed
EM
2
Elliott Management
New York
– -$17.6M -20,428,961 Closed
MCM
3
Mason Capital Management
New York
– -$12.6M -14,644,398 Closed
TGHSA
4
TPG Group Holdings (SBS) Advisors
Texas
– -$11.4M -13,240,462 Closed
BCM
5
Brigade Capital Management
New York
– -$11M -12,765,651 Closed
FCM
6
Farallon Capital Management
California
– -$7.91M -9,195,584 Closed
WA
7
Whitebox Advisors
Minnesota
– -$5.98M -6,956,279 Closed
NGA
8
New Generation Advisors
Massachusetts
– -$4.94M -5,744,776 Closed
HCM
9
Highbridge Capital Management
New York
– -$4.62M -3,907,852 Closed
MFP
10
Michael F. Price
– -$3.08M -3,583,668 Closed
BHMP
11
Bardin Hill Management Partners
New York
– -$2.84M -3,300,182 Closed
JCI
12
Jet Capital Investors
New York
– -$2.44M -2,832,053 Closed
AMH
13
Apollo Management Holdings
New York
– -$1.53M -1,774,782 Closed
Capstone Investment Advisors
14
Capstone Investment Advisors
New York
– -$1.33M -1,542,395 Closed
OP
15
Omni Partners
United Kingdom
– -$1.24K -1,446,247 Closed
CL
16
CSS LLC
Illinois
– -$1.01M -1,170,626 Closed
UOC
17
UBS O'Connor
Illinois
– -$1M -1,162,096 Closed
GF
18
Gabelli Funds
New York
– -$594K -690,000 Closed
Goldman Sachs
19
Goldman Sachs
New York
– -$533K -620,135 Closed
Adage Capital Partners
20
Adage Capital Partners
Massachusetts
– -$529K -614,455 Closed
TA
21
Teton Advisors
New York
– -$344K -400,000 Closed
BMO
22
Beck Mack & Oliver
New York
– -$245K -284,245 Closed
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
– -$234K -271,641 Closed
BFM
24
Boothbay Fund Management
New York
– -$210K -243,574 Closed
TL
25
TowerView LLC
New York
– -$181K -210,000 Closed
1
2 3

GCVRZ Hedge Fund Activity: Q1 2020 in Review

2 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2020, worth a combined $0 — down 100% from $140M a quarter earlier.

Sellers outnumbered buyers: 98 funds closed out of GCVRZ and 0 opened new positions — a net loss of 98 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Stonehill Capital Management, exiting entirely with an estimated $46.8M sold.

  • 2 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2020, down from 103 in Q4 2019.
  • Funds reported $0 of Sanofi Contingent Value Rights stock for Q1 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Sanofi Contingent Value Rights positions in Q1 2020 and 98 closed out, a net change of -98 holders.
  • The largest Sanofi Contingent Value Rights seller in Q1 2020 was Stonehill Capital Management, an estimated $46.8M sold.

Based on aggregated 13F filings for Q1 2020.